The association of hyperuricemia and maternal and fetal outcomes among pregnant women: a meta-analysis

Abstract

Objective

This meta-analysis aimed to investigate the relationship between hyperuricemia and maternal and neonatal complications in pregnant women.

Methods

We searched PubMed, Embase, Web of Science, and the Cochrane Library from the databases’ inception to August 12, 2022. We included studies that reported results on the association between hyperuricemia and maternal and fetal outcomes among pregnant women. Using the random-effects model, the pooled odds ratio (OR) with 95% confidence intervals (CIs) was calculated for each outcome analysis.

Results

A total of 7 studies, including 8104 participants, were included. The pooled OR for pregnancy-induced hypertension (PIH) was 2.61 [0.26, 26.56] (z = 0.81, p = .4165; I² = 96.3%). The pooled OR for preterm birth was 2.52 [1.92, 3.30] (z = 6.64, p < .0001; I² = 0%). The pooled OR for low birth weight (LBW) was 3.44 [2.52, 4.70] (z = 7.77, p < .0001; I² = 0%). The pooled OR for small gestational age (SGA) was 1.81 [0.60, 5.46] (z = 1.06, p = .2912; I² = 88.6%).

Conclusion

Results of this meta-analysis indicate a positive relationship between hyperuricemia and PIH, preterm birth, LBW, and SGA in pregnant women.

Keywords:

• Hyperuricemia
• pregnancy
• maternal outcomes
• fetal outcomes
• meta-analysis

Ethical approval

Not Applicable

Consent form

Not Applicable

Author contributions

Jie Tan conceived and designed this study. Xuhong Zhu administrative support. Huali Fei performed the collection, extraction, and analysis of data. Jie Tan was responsible for writing the manuscript. Lumeng Chen modified the English language. All authors reviewed the paper and approved the final manuscript.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data Availability statement

The datasets generated and/or analyzed during the current study are available in the article.

Additional information

Funding

This study was supported by Research on Digital Diagnosis and Treatment Platform of Perinatal Nutrition and Intelligent Application of Key Technologies, Hangzhou Bio-medicine and Health Industry Development Support Science and Technology Special [2021WJCY332].